Early Treatment with Bamlanivimab Alone does not Prevent COVID-19 Hospitalization and Its Post-Acute Sequelae. A Real Experience in Umbria, Italy

BACKGROUND AND OBJECTIVE: The use of monoclonal antibodies to the SARS-Cov-2 spike protein for early treatment of COVID-19 disease is being evaluated, with only phase 2 studies available to date. The emergency authorization of bamlanivimab monotherapy was obtained in November 2020 by the FDA and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiaroli, Elisabetta, De Socio, Giuseppe Vittorio, Martinelli, Laura, Malincarne, Lisa, Savoia, Martina, Spinelli, Anna Laura, Francisci, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577560/
https://www.ncbi.nlm.nih.gov/pubmed/34804435
http://dx.doi.org/10.4084/MJHID.2021.061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577560/
https://www.ncbi.nlm.nih.gov/pubmed/34804435
http://dx.doi.org/10.4084/MJHID.2021.061

Ejemplares similares